annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 30C Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies
for resectable pancreatic cancer (PC). (Abstract #4125)
R. T. Shroff, M. M. Javle, S. Krishnan, S. B. Cantor, J. E. Lee, J. B. Fleming,
G. R. Varadhachary, J. L. Abbruzzese, R. A. Wolff, L. S. Elting
Brd. 31A Association of elevated tissue factor (TF) with survival and
thromboembolism (TE) in pancreaticobiliary cancers (PBC). (Abstract #4126)
A. Bharthuar, A. A. Khorana, A. Hutson, J. Wang, N. Mackman, R. V. Iyer
Brd. 31B Characterization and prognostic significance of circulating tumor cells in the
peripheral blood of patients with metastatic pancreatic cancer. (Abstract
#4127)
B. P. Negin, N. J. Meropol, R. K. Alpaugh, K. Ruth, C. McAleer, T. Halbherr,
C. Bingham, P. Fittipaldi, S. J. Cohen
Brd. 31C Use of tumor arterial perfusion assessment and RECIST for prediction of
survival and residual disease in hepatocellular carcinoma following
intra-arterial infusion chemotherapy. (Abstract #4128)
J. R. Daniels, M. A. Wallman, J. A. Donovan, A. B. El-Khoueiry, S. Iqbal, M. Hart,
J. Pena
Brd. 32A Analysis of D7S486 in primary gastric cancer and evaluation of TESTIN as a
candidate tumor suppressor gene. (Abstract #4129)
J. Xia, D. Weng, H. Ma, Y. Chen, W. Huang, K. Pan
Brd. 32B Dynamic changes in age, stage distribution, and survival of patients with
esophageal adenocarcinoma over three decades in the United States.
(Abstract #4130)
P. Cen, F. Banki, L. Cheng, L. R. Kaiser, K. Khalil, X. L. Du, R. J. Amato
Brd. 32C Identification of three potential biomarkers in early resectable hepatocellular
carcinoma. (Abstract #4131)
S. Ang, W. Wang, Y. Soe, C. Tan, W. Chow, A. K. Kwee, H. Toh
Brd. 33A Clinical outcomes and survival in patients with hepatocellular carcinoma and
HIV infection. (Abstract #4132)
M. Berretta, E. Garlassi, P. Ventura, B. Cacopardo, A. Lleshi, S. Cocchi,
G. Guaraldi, A. Pietrangelo, U. Tirelli
Brd. 33B Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and
mTOR) in patients with advanced gastric and gastroesophageal junction
(GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX
study. (Abstract #4133)
C. Pinto, V. Mutri, F. Di Fabio, S. Giaquinta, C. Ceccarelli, F. L. Rojas Llimpe,
P. Di Tullio, C. Barone, S. Siena, A. Martoni
Brd. 33C A phase I dose escalation trial of CP-675206 (tremelimumab) in combination
with gemcitabine in patients with chemotherapy-naive metastatic pancreatic
cancer. (Abstract #4134)
M. Aglietta, C. Barone, M. Muliello, C. Bagalà, D. Ferraro, K. D. Fly, B. Huang,
F. Leone
Brd. 34A Clinical outcome of local recurrence cases after endoscopic mucosal
resection (EMR) for Japanese Classification stage 0 esophageal cancer.
(Abstract #4135)
T. Yoshii, S. Ohkawa
Brd. 34B A phase I study, with expanded cohort, of biweekly fixed-dose rate
gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced
pancreatic (APC) and biliary carcinomas (ABC). (Abstract #4136)
A. M. Espinoza, A. H. Ko, A. P. Venook, E. K. Bergsland, K. A. Jones, R. K. Kelley,
W. M. Korn, E. Dito, A. Ong, M. A. Tempero
Brd. 34C Final results from ARQ 197–114: A phase Ib safety trial evaluating ARQ 197 in
cirrhotic patients (pts) with hepatocellular carcinoma (HCC). (Abstract #4137)
P. Zucali, A. Santoro, C. Rodriguez-Lope, M. Simonelli, L. H. Camacho,
N. N. Senzer, L. Bolondi, M. Lamar, G. Abbadessa, B. E. Schwartz
274